X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3753) 3753
Book Chapter (14) 14
Magazine Article (11) 11
Dissertation (6) 6
Conference Proceeding (5) 5
Government Document (3) 3
Book / eBook (1) 1
Publication (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sofosbuvir (2636) 2636
humans (2231) 2231
hepatitis c (1788) 1788
hepatitis c virus (1527) 1527
antiviral agents - therapeutic use (1382) 1382
ribavirin (1339) 1339
gastroenterology & hepatology (1248) 1248
hepatitis c, chronic - drug therapy (1245) 1245
male (1179) 1179
female (1092) 1092
hepatitis (1043) 1043
middle aged (1041) 1041
interferon (893) 893
hepacivirus - genetics (853) 853
genotype (836) 836
ledipasvir (789) 789
drug therapy, combination (785) 785
hcv (775) 775
antiviral agents (764) 764
treatment outcome (762) 762
infection (707) 707
adult (669) 669
cirrhosis (644) 644
hepatitis c - drug therapy (632) 632
virus-infection (617) 617
aged (613) 613
infectious diseases (591) 591
therapy (579) 579
sofosbuvir - therapeutic use (566) 566
health aspects (565) 565
hepacivirus - drug effects (550) 550
pharmacology & pharmacy (520) 520
liver (518) 518
antiviral agents - administration & dosage (505) 505
patients (505) 505
infections (502) 502
sustained virological response (490) 490
ribavirin - therapeutic use (483) 483
antiviral agents - adverse effects (463) 463
daclatasvir (456) 456
hepatitis c, chronic - virology (451) 451
care and treatment (437) 437
sustained virologic response (437) 437
analysis (431) 431
drug therapy (424) 424
liver cirrhosis (404) 404
genotype 1 infection (396) 396
genotype 1 (385) 385
virology (385) 385
direct-acting antivirals (374) 374
viruses (371) 371
genotype & phenotype (366) 366
uridine monophosphate - analogs & derivatives (366) 366
simeprevir (333) 333
genotypes (328) 328
transplantation (317) 317
treatment-naive patients (309) 309
efficacy (306) 306
hepatitis-c virus (305) 305
biological response modifiers (304) 304
liver transplantation (301) 301
virus diseases (298) 298
medicine, general & internal (295) 295
hepatitis c, chronic - complications (294) 294
genetic aspects (278) 278
immunology (277) 277
sofosbuvir - administration & dosage (274) 274
velpatasvir (272) 272
treatment-naive (268) 268
pegylated interferon (265) 265
abridged index medicus (262) 262
hepatology (260) 260
uridine monophosphate - therapeutic use (259) 259
open-label (258) 258
safety (257) 257
plus ribavirin (256) 256
hcv infection (255) 255
antiviral agents - pharmacology (253) 253
microbiology (253) 253
prevalence (253) 253
retrospective studies (247) 247
liver diseases (246) 246
gastroenterology and hepatology (243) 243
hepatitis c - virology (239) 239
medical research (237) 237
sofosbuvir plus ribavirin (236) 236
benzimidazoles - therapeutic use (230) 230
young adult (230) 230
ribavirin - administration & dosage (229) 229
antiviral therapy (225) 225
hepacivirus (223) 223
united-states (221) 221
fibrosis (219) 219
combination (218) 218
sofosbuvir - adverse effects (217) 217
recurrence (215) 215
fluorenes - therapeutic use (213) 213
chronic hepatitis-c (211) 211
research (206) 206
clinical trials (205) 205
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3606) 3606
Korean (60) 60
German (50) 50
Spanish (30) 30
French (14) 14
Hungarian (10) 10
Japanese (10) 10
Chinese (8) 8
Russian (8) 8
Czech (6) 6
Dutch (1) 1
Italian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2017, Volume 153, Issue 1, pp. 113 - 122
Background & Aims Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment... 
Gastroenterology and Hepatology | Direct-Acting Antiviral Agent | Shortened Duration Therapy | Clinical Trial | Comparison | PROTEASE INHIBITOR GS-9857 | SIMEPREVIR PLUS SOFOSBUVIR | COMBINATION | CHALLENGES | GENOTYPE 1 | TREATMENT-NAIVE | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | DIRECT-ACTING ANTIVIRALS | GASTROENTEROLOGY & HEPATOLOGY | Humans | Middle Aged | Male | Carbamates - administration & dosage | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Sofosbuvir - administration & dosage | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Sulfonamides - administration & dosage | Medical colleges | Care and treatment | Protease inhibitors | Proteases | Transplantation of organs, tissues, etc | Product development | Hepatitis C virus | Hepatitis C | Health aspects | Analysis
Journal Article
Journal Article
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 2016, Volume 63, Issue 11, pp. 1405 - 1411
Background. Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment... 
Hepatitis C virus | DAA | Drug use | PWID | Opioid substitution therapy | UNITED-STATES | INFECTIOUS DISEASES | METAANALYSIS | SOFOSBUVIR | MICROBIOLOGY | IMMUNOLOGY | LEDIPASVIR | HEPATITIS-C VIRUS | REINFECTION | hepatitis C virus | drug use | opioid substitution therapy | INJECT DRUGS | PEOPLE | USERS | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Drug Users | Drug Therapy, Combination - adverse effects | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Opiate Substitution Treatment | Retrospective Studies | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Data Interpretation, Statistical | Enzyme-Linked Immunosorbent Assay | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Sustained Virologic Response | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Treatment outcome | Safety and security measures | Analysis | Dosage and administration | Hepatitis C | Drug therapy | Ribavirin
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 2016, Volume 63, Issue 11, pp. 1479 - 1481
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 10/2016, Volume 63, Issue 8, pp. 1042 - 1048
Journal Article
Journal Article